Deals this week: Cancer Genetics, InstaMed Communications, EIT Emerging Implant Technologies

29 September 2016 (Last Updated September 29th, 2016 18:30)

Oncologic diagnostics provider Cancer Genetics has agreed to work with MD Anderson Cancer Centre’s spin-out ApoCell, in order to make its ApoStream liquid biopsy technology available to pharmaceutical and biotech companies.

Oncologic diagnostics provider Cancer Genetics has agreed to work with MD Anderson Cancer Centre’s spin-out ApoCell, in order to make the latter's ApoStream liquid biopsy technology available to pharmaceutical and biotech companies.

ApoStream is a high-performance platform for the detection, isolation and capture of circulating tumour cells (CTC) and other rare cells, and does not require labels or antibodies.

The strategic alliance and partnership between the two companies allows them to collaborate on conducting clinical trials using the platform for both targeted therapeutics and immuno-oncology. They will also advance evaluation of applications for patient monitoring in different cancers where drug resistance impacts patient response and outcome.

Healthcare payments solutions provider InstaMed Communications has secured a $50m investment from Carrick Capital Partners, a private equity firm that focuses on technology-enabled businesses.

"InstaMed plans to use the investment to expand its network, further advance and innovate healthcare payments technology, and drive its go-to-market strategy."

InstaMed plans to use the investment to expand its network, further advance and innovate healthcare payments technology, and drive its go-to-market strategy.

Cowen and Company served as the financial adviser for the transaction.

3D spinal implants manufacturer EIT Emerging Implant Technologies has received funding from SHS Gesellschaft fur Beteiligungsmanagement, a publicly funded investment company.

EIT will use the investment to expand into international markets, especially the US, to develop new and innovative product range.

Tissue closure solutions specialise SentreHEART has raised $35m in a series D financing round led by Deerfield Management Company.

The round has also seen the participation of existing investors US Venture Partners, Prospect Venture Partners, Vivo Capital and Decheng Capital.

SentreHEART plans to use the proceeds to complete a clinical trial named aMAZE, which evaluates the use of its proprietary LARIAT device for left atrial appendage closure (LAAC) to treat persistent or long-standing persistent atrial fibrillation (AFib).

American multinational company PerkinElmer has announced plans to spin-out its reproductive health-focused diagnostics business, effective from 3 October.

The company will also merge its environmental health and life sciences solutions businesses into a discovery and analytical solutions division, which will develop new products for the food, environmental, industrial and life sciences market.


Image: LARIAT technology is used for non-implant left atrial appendage closure (LAAC) in patients with AFib. Photo: courtesy of SentreHEART.